Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.
AIDS-related Kaposi sarcoma (KS) is often incompletely controlled, requiring serial therapies. KS herpesvirus (KSHV) induces transformation of endothelial cells, where it resides in a predominately latent state. We hypothesized proteasome inhibition would have direct anti-tumor activity, induce lytic activation of KSHV, and inhibit HIV infectivity, improving control of both KS and HIV. The primary objective was determining the maximum tolerated dose (MTD) of bortezomib in AIDS-KS. Secondary objectives included estimating the impact of bortezomib on KS response, KSHV plasma DNA copy number (PDCN) and HIV viral loads (VL). A 3+3 dose escalation design was employed evaluating 4 dose levels of bortezomib (0.75, 1, 1.2, or 1.6 mg/m2) administered intravenously on days 1, 8, and 15 of 28-day cycles in patients with relapsed/refractory (r/r) AIDS-KS taking antiretroviral therapy. Seventeen patients enrolled. No dose limiting toxicities occurred and the MTD was not reached. The most common adverse events included diarrhea, fatigue and nausea. Among 15 patients evaluable, partial response (PR) occurred in 9 (60%), with PR rate of 83% in the 1.6 mg/m2cohort; the remainder had stable disease (SD). Median time to response was 2.1 months. Median change in KSHV PDCN was significantly different between those with PR versus SD. During cycle 1, 7 of 11 evaluable patients had decreases in HIV VL. Bortezomib is well-tolerated and active in AIDS-KS. The 60% PR rate is notable given the dose-finding nature of the study in a r/r population. Changes in KSHV PDCN and HIV VL trended as hypothesized.